Xencor (XNCR) to Post Earnings on Wednesday

Xencor (NASDAQ:XNCR) is projected to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.8017) per share and revenue of $18.8890 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The firm had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The firm’s quarterly revenue was down 86.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.66) EPS. On average, analysts expect Xencor to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Xencor Stock Performance

XNCR stock opened at $19.40 on Tuesday. The company has a market capitalization of $1.44 billion, a PE ratio of -8.47 and a beta of 0.85. Xencor has a one year low of $6.92 and a one year high of $21.76. The company’s 50 day moving average price is $15.03 and its two-hundred day moving average price is $13.18.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XNCR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Wedbush reissued an “outperform” rating and issued a $26.00 price target on shares of Xencor in a research note on Thursday, July 30th. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Truist Financial reduced their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. raised their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Xencor currently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

Institutional Trading of Xencor

A number of institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its holdings in Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares during the period. E Fund Management Co. Ltd. purchased a new stake in Xencor in the 2nd quarter worth approximately $79,000. iSAM Funds UK Ltd bought a new stake in shares of Xencor in the 2nd quarter worth approximately $122,000. Prelude Capital Management LLC bought a new stake in shares of Xencor in the 3rd quarter worth approximately $139,000. Finally, Creative Planning increased its stake in shares of Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 3,661 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.